Search Results
Your search for what matches 6238 pages
Showing 3601 - 3650Decision Aid Improves Breast Cancer Patients’ Knowledge of Surgical Options
A Web-based decision aid that allows women with early breast cancer to easily compare surgical treatment options helps them make more informed decisions, suggests a randomized trial reported at the 2017 Society of Surgical Oncology (SSO) Annual Cancer Symposium.1 “Having knowledge of surgical...
Machine Learning Model Predicts Colorectal Cancer Recurrence
A machine learning model that uses a set or ensemble of algorithms has good accuracy for predicting colorectal cancer recurrence, investigators reported during a plenary session at the 2017 Society of Surgical Oncology (SSO) Annual Cancer Symposium.1 Persistent key questions in managing early...
How ASCO’s CancerLinQ Discovery™ Will Help Speed Research Advances and Improve Patient Outcomes
This past November, ASCO announced the launch of CancerLinQ Discovery™, a big data learning platform physicians and researchers can use to analyze highly curated, de-identified, real-world cancer care data sets to broaden their clinical knowledge about specific cancers and eventually improve...
Dual HER2 Targeting of HER2-Positive Metastatic Colorectal Cancer Shows Clinical Benefit
The combination of trastuzumab (Herceptin) plus lapatinib (Tykerb) achieved positive results in patients with heavily pretreated, HER2-positive metastatic colorectal cancer, according to the final results of the phase II HERACLES-A trial. This two-pronged, HER2-directed approach achieved clinical...
Possible Link Between Androgen-Deprivation Therapy and Dementia
A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen-deprivation therapy and dementia, according to researchers from the Perelman School of Medicine at the University of Pennsylvania. Previous studies from Penn have shown men who undergo...
U.S. Preventive Services Task Force Seeks Comments on Draft Recommendation Statement on Screening for Prostate Cancer
On April 11, the U.S. Preventive Services Task Force (USPSTF) posted for public comment a draft recommendation statement and three draft evidence reviews on screening for prostate cancer. Through this draft recommendation, the Task Force is providing clinicians and their patients with...
Preclinical Research Suggests Potential Therapy for 'Chemobrain'
Findings offered by a University of Kansas (KU) researcher at the national meeting of the American Chemical Society in early April suggest a possible therapeutic intervention for “chemobrain,” the cognitive impairment that plagues up to a third of cancer patients following chemotherapy. ...
Annual Report to the Nation: Cancer Death Rates Continue to Decline
Overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups, according to the latest Annual Report to the Nation on the Status of Cancer, 1975–2014, published by Jemal et al in the Journal of the National Cancer Institute. The report...
Increased Recognition of Colorectal Cancer in Young Adults, Even Those Aged 20 to 29, as Evidence Continues to Accumulate
The incidence of colorectal cancer continues to increase among young adults, with the sharpest increase among those aged 20 to 29, according to a recent article in the Journal of the National Cancer Institute.1 This trend has been called disturbing and ominous, but the widely reported results of...
Forging a New Role to Make Curing More Cancers a Reality
For more than 3 decades, Nancy E. Davidson, MD, has dedicated her clinical and research career to better understanding the molecular mechanisms driving the development of breast cancer and to the discovery of more effective therapies to treat the disease. The recipient of an ASCO Young...
Practice-Changing Research: Making Palliative Care a Routine Part of Cancer Care in the United States and Abroad
With its recently issued clinical practice guideline update, reviewed in this issue of The ASCO Post, ASCO has spoken: Interdisciplinary palliative care teams improve the outcomes of cancer care; patients live longer and feel better.1 There is no doubt. Multiple well-designed studies show the...
Cardiac Dysfunction in Survivors of Adult Cancers
The success of cancer therapy has led us to an interesting place. Patients with cancer are certainly concerned about collateral damage that may occur with the treatment of their condition; however, impressive improvements in survival with treatment of many cancers are so compelling that these...
ASCO Clinical Practice Guideline on Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers
As reported in the Journal of Clinical Oncology by Saro H. Armenian, DO, MPH, of City of Hope, and colleagues, ASCO has released a clinical practice guideline on prevention and monitoring of cardiac dysfunction in survivors of adult cancers.1 Recommendations were developed by an expert panel...
Young Women With Metastatic Breast Cancer: Unique Needs and Concerns
Patients with breast cancer who perceive having enough and the right kinds of social support tend to be less stressed, although a paucity of research exists on the social support needs of young women with metastatic breast cancer, according to Amanda Ginter, PhD. Dr. Ginter, Assistant Professor in ...
New Constructs for Use in the Identification of Depression in Older Patients With Cancer
Elderly patients with cancer are far less likely to be diagnosed with depression than patients in any other age group for two primary reasons: There is an overlap between cancer symptoms/treatment side effects and the diagnostic criteria for depression, and older adults are more likely to present...
CancerLinQ: Big Data for Quality Benchmarking
At this year’s ASCO Quality Care Symposium, CancerLinQ’s Vice President and Medical Director, Robert S. Miller, MD, shed light on CancerLinQ’s current and future value in the oncology community.1 Dr. Miller opened by explaining to the audience that CancerLinQ™ is an instrument for quality...
Harnessing Implementation Science to Improve Cancer Care Delivery
Implementation science encompasses the study of methods to accelerate integration of evidence into practice and policy to improve health-care outcomes. At the 2017 ASCO Quality Care Symposium, Sandra A. Mitchell, PhD, CRNP, of the Division of Cancer Control and Population Sciences at the National...
AACR 2017: IDH-Mutant Cancers May Be More Amenable to Treatment With PARP Inhibitors Than IDH Inhibitors, According to Preclinical Findings
Tumors with mutations in the proteins isocitrate dehydrogenase-1 or -2 (IDH1/2) exhibited features similar to BRCA-mutant tumors and were more likely to respond better to PARP inhibitors than to IDH inhibitors, according to preclinical data presented by Sulkowski et al at the 2017 American...
Expert Point of View: Shridar Ganesan, MD, PhD
Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discussed the study on the gut microbiome. Dr. Ganesan noted that response to immunotherapy depends not only on tumor characteristics, but on the immune microenvironment as well, and this can clearly be influenced by host...
The Mystery of Grace
The day after I told Nell she had seven metastases to her brain, she sent me flowers. She was my patient; I was her oncologist. I had met her 1 year prior, when she was well into her cancer journey, stage IV breast cancer at diagnosis. I took over from her current oncologist, who was moving. At...
Expert Point of View: Eloise Chapman-Davis, MD
Eloise Chapman-Davis, MD, a gynecologic oncologist at New York-Presbyterian and Weill Cornell Medicine, commented on the SOLO2 trial results for The ASCO Post. “SOLO2 is the third randomized trial to evaluate the use of maintenance therapy in a selected subgroup of ovarian cancer patients with...
AACR 2017: Patients With Triple-Negative Breast Cancer Who Responded to Atezolizumab Had Long-Term Survival Benefit
Among patients with metastatic triple-negative breast cancer who were treated with the anti–programmed death-ligand 1 (PD-L1) immunotherapy atezolizumab (Tecentriq), those who responded to the treatment had a longer overall survival compared with those who did not respond, according to data...
AACR 2017: 5-Year Survival Rate for Nivolumab-Treated Advanced Lung Cancer Higher Than Historical Rate in Early-Phase Trial
Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with advanced non–small cell lung cancer (NSCLC), with a 5-year survival rate of 16%, according to data from a phase I clinical trial presented by Brahmer et al at the American...
ASCO and Cancer Care Ontario Update Guideline on Radiation Therapy for Prostate Cancer
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy for patients with prostate cancer. The update provides evidence-based recommendations for different patient risk groups and specifies the most effective...
New Study Finds Most Cancer Mutations Due to Random DNA-Copying Errors
Johns Hopkins Kimmel Cancer Center scientists report data from a new study providing evidence that random, unpredictable DNA copying “mistakes” account for nearly two-thirds of the mutations that cause cancer. Their research is grounded on a novel mathematic model based on DNA...
David G. Pfister, MD, on HPV and Head and Neck Cancer
David G. Pfister, MD, of Memorial Sloan Kettering Cancer Center, discusses the link between human papillomavirus and oropharyngeal cancers and what is known about the effect of HPV on treatment response and outcome.
Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer
Christina S. Chu, MD, of Fox Chase Cancer Center, discusses the link between human papillomavirus and genital cancers and what is known about the effect of HPV on treatment response and outcome.
An Evening for Cancer Survivors and Caregivers: Bringing Together a Community of Support
On January 26, 2017—prior to the official opening of the 2nd Annual Cancer Survivorship Symposium—cancer survivors, caregivers, patient advocates, family physicians, oncology providers, and others gathered in San Diego, California, to make connections, discuss survivorship issues, and get expert...
Examining the Impact of ‘Death With Dignity’ Legislation
Despite the controversy surrounding “Death With Dignity” laws, which allow physicians to prescribe life-ending drugs to terminally ill patients, they have a long history of majority support from Americans. According to a Gallup poll taken in 2015, nearly 7 in 10 Americans (68%) agreed that...
Coping With an Uncommon Cancer
In April 2014, I was so sick with uncontrollable vomiting and diarrhea and severe abdominal and chest pain that I had to be hospitalized for 5 days. As I was in my late 20s and in otherwise good health, there was no easy explanation for my symptoms. After I was released from the hospital, my...
Acupuncture for the Management of Hot Flashes
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, authors Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, present a case study...
New First-Line Options for ALK-Positive Lung Cancer on the Horizon
Anaplastic lymphoma kinase (ALK) rearrangements define a subset of non–small cell lung cancer (NSCLC) patients for whom ALK inhibitors are highly effective. In PROFILE 1014, the multitargeted ALK inhibitor crizotinib (Xalkori) was shown to be superior to platinum/pemetrexed (Alimta) chemotherapy...
ASCO Addresses New Policies That Threaten Access to Opioids
Since the mid-2000s, medication and illicit drug abuse in the United Sates has steadily increased, creating what has now been termed an “opioid epidemic.” In response, Congress and the Bush and Obama Administrations have launched intervention and regulatory proposals to help turn the troubling...
The Art of Medicine in the World of Evidence-Based Medicine
Christian Taverna, MD, a lymphoma specialist at the Hospital Münsterlingen in Switzerland, commented on this patient series for The ASCO Post. He noted that the Swiss Group for Clinical Cancer Research (SAKK) tried to address the question of the optimal duration of rituximab (Rituxan) maintenance...
For One Hematologist, No Disease Progressions in Follicular Lymphoma With Rituximab Maintenance
Patients with follicular lymphoma are clearly living longer without disease progression, but what clinician has had no patients progress? Michael Auerbach, MD, a hematologist/oncologist in private practice in Baltimore and Clinical Professor of Medicine at Georgetown University, may have these...
Expert Point of View: Heather L. McArthur, MD, MPH
Study discussant Heather L. McArthur, MD, MPH, Medical Director of Breast Oncology at Cedars-Sinai Medical Center, Los Angeles, noted that human papillomavirus (HPV) vaccination has been shown to prevent HPV-related malignancies and eradicate high-grade, HPV16-positive premalignant lesions....
Expert Point of View: Joseph Greer, PhD
“These data are consistent with other studies we have conducted in advanced lung cancer, in which we similarly found that one-third of patients believed that their metastatic lung cancer was curable. These patients ostensibly already had conversations with their oncologists about their prognosis...
Aligning Patient Expectations With Treatment Goals in the Metastatic Setting
More than one-third of men with incurable metastatic prostate cancer mistakenly believe that their cancer may be curable, according to a survey of patient expectations at an academic cancer center. “This study is part of a larger survey of treatment decision-making among men with metastatic...
IASLC Endorses Tobacco Reform Report Outlining Progress Toward Ending Adult Cigarette Smoking
The International Association for the Study of Lung Cancer (IASLC) has endorsed a report released by the Core Team for Tobacco Control that outlines key action items that can be taken immediately to accelerate progress toward ending cigarette smoking in adults. Issuing their Executive Summary ...
Making the Case for Sentinel Node Biopsy in Early Cancers of the Oral Cavity
“The majority of patients with oral cavity cancers will undergo an unnecessary operation,” Sandeep Samant, MD, stated at a session on managing N0 neck cancer at the 2016 Lurie Cancer Center Multidisciplinary Head & Neck Symposium in Chicago.1 That operation is elective neck dissection, and it ...
Online Symptom-Management Curriculum May Improve Depression and Fatigue in Breast Cancer Survivors
With thousands of devices to track and manage health and wellness, eHealth tools are beginning to transform modern health care and research, demonstrating quantifiable improvements in patient outcomes. According to the results of a randomized controlled trial (Reimagine), breast cancer survivors...
Expert Point of View: Nancy Baxter, MD, PhD & Steven H. Lin, MD, PhD
“CALGB 80803 really helps move the field forward,” said press briefing moderator and ASCO spokesperson Nancy Baxter, MD, PhD, a surgeon from St. Michael’s Hospital in Toronto, Ontario, Canada. “PET [positron-emission tomography] scans may prove to be a valuable tool to help oncologists fine-tune...
Expert Point of View: Milind Javle, MD
Milind Javle, MD, Professor of Gastrointestinal Oncology at The University of Texas MD Anderson Cancer Center, Houston, discussed the findings from the CheckMate 040 trial presented at the 2017 Gastrointestinal Cancers Symposium. There is a strong rationale for investigating immunotherapy in liver ...
Nivolumab Shows Benefit in Advanced Hepatocellular Carcinoma
In patients with advanced hepatocellular carcinoma, treatment with nivolumab (Opdivo) resulted in responses and long-term survival in patients who were either previously treated or naive to sorafenib (Nexavar), CheckMate 040 has shown.1 Altogether 19% of patients responded to the antibody...
Progress Being Made in Understanding Immunotherapy Resistance
A key challenge in advancing immunotherapies is to understand mechanisms of response and resistance. Emerging research in this area—including evidence that early on-treatment biopsies can predict response—was discussed at the 2017 ASCO-SITC (Society for Immunotherapy of Cancer) Clinical...
The Path Forward for Clinical Pathways in Oncology
The year 2016 was a memorable one for oncology. In January, President Barack Obama announced the launch of the National Cancer Moonshot initiative, spearheaded by Vice President Joe Biden, which aims to accelerate cancer research. And in December, through bipartisan Congressional support, the 21st ...
Pembrolizumab Affords Long-Term Survival to One-Fourth of Selected Patients With NSCLC, Alternative Statistical Model Suggests
Statistical modeling of long-term survival from the KEYNOTE trials of the programmed cell death protein 1 (PD-1)–inhibitor pembrolizumab (Keytruda) estimates that one-quarter of appropriately selected patients with advanced non–small cell lung cancer (NSCLC) may attain long-term survival.1 “In...
SGO 2017: Hospital Readmission Metrics May Not Be an Ideal Measure in Ovarian Cancer Cases
To reduce costs and improve quality of care, the Centers for Medicare & Medicaid Services (CMS) has made reducing hospital readmission rates a priority, yet two research studies presented at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer question the use...
Clinical Practice Committee, State Affiliate Council Support Innovative Clinical Research—And So Can You
ASCO’s Clinical Practice Committee (CPC) and State Affiliate Council (SAC) have a history of supporting the Conquer Cancer Foundation of ASCO (CCF) Young Investigator Award (YIA) program. Individual members of the Clinical Practice Committee and State Affiliate Council, as well as ASCO State...
Low-Grade Gliomas: Understanding the New Treatment Paradigm
Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed, as detailed in a recent review in the Journal of Oncology Practice.1 The...
